| 基因多态性对氨氯地平药代、药效的影响 |
| |
| 引用本文： | 杨夏玲,杨婧芝,熊玉卿. 基因多态性对氨氯地平药代、药效的影响[J]. 中国临床药理学与治疗学, 2011, 16(4): 455-460 |
| |
| 作者姓名： | 杨夏玲 杨婧芝 熊玉卿 |
| |
| 作者单位： | 1. 南昌大学医学院临床药理研究所;南昌大学第二附属医院科教科,南昌330006,江西
2. 南昌大学医学院临床药理研究所 |
| |
| 基金项目： | 国家"十一五"科技重大专项"建立新药研发安全监测信息化技术平台"子课题 |
| |
| 摘 要： | 氨氯地平是二氢吡啶钙离子通道阻滞剂,临床上用于各种高血压和心绞痛的治疗,在体内经CYP3A5代谢而消除,其药代动力学不同于其他的二氢吡啶钙离子通道阻滞剂。由于CYP3A存在基因多态性而导致氨氯地平药代动力学的个体差异。为此,笔者查阅国内外相关文献对氨氯地平的临床应用与CYP3A5基因多态性对其药代动力学及药效学的影响进行综述,为临床参考基因多态性特征来确立氨氯地平正确合理的给药方案提供依据。
|
| 关 键 词： | CYP3A5 氨氯地平 药动学 药效学 |
Effects of polymorphic gene on the pharmacokinetics and pharmacodynamics of amlodipine |
| |
| YANG Xia-ling,YANG Jing-zhi,XIONG Yu-qing. Effects of polymorphic gene on the pharmacokinetics and pharmacodynamics of amlodipine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(4): 455-460 |
| |
| Authors: | YANG Xia-ling YANG Jing-zhi XIONG Yu-qing |
| |
| Affiliation: | YANG Xia-ling1,YANG Jing-zhi2,XIONG Yu-qing2 1The Second Affiliated Hospital of Nanchang University,2Institute of Clinical Pharmacology,Medical College of Nanchang University,Nanchang 330006,Jiangxi,China |
| |
| Abstract: | Amlodipine,1,4-Dihydropyridine calcium channel antagonists,prescribed in the management of angina and hypertension,act as substrates of CYP3A5,has a pharmacokinetic profile that differs from other dihydropyridines.It has been suggested that the CYP3A5*3 allele contributes to the interindividual variability of CYP3A activity in vivo.This review aimed to summarize the clinical application of the amlodipine and the possible role of the genetic polymorphism CYP3A5 on the pharmacokinetics and pharmacodynamics of... |
| |
| Keywords: | CYP3A5 Amlodipine Pharmacokinetics Pharmacodynamics |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
